Corbus Pharmaceuticals is dedicated to the development of CRB-913 as a potential treatment option for obesity.
Public source
Publisher name
Public post
Obesity has become a global health crisis, doubling in prevalence since 1990 and significantly increasing the risk of heart disease, diabetes, certain cancers, and muscu…
Company
Corbus Pharmaceuticals
Connecting innovation to purpose to improve the futures of cancer and obesity patients.
- Industry
- Pharmaceutical Manufacturing
- Location
- Norwood, US
- Company size
- 51–200 employees
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Novo Nordisk
Novo Nordisk published results from a large late-stage clinical trial showing that 40.4% of children moved from the obesity BMI category to the overweight or even healthy-weight category.
Research & Knowledge
PILA PHARMA
PILA PHARMA released its regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist, a potential first-in-class candidate.
Research & Knowledge
Structure Therapeutics
Structure Therapeutics reported positive top-line clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, advancing its goal of creating a best-in-industry oral chronic weight management portfolio.
Research & Knowledge
WuXi AppTec, Laboratory Testing Division
WuXi AppTec, Laboratory Testing Division published a blog post arguing that the next wave of GLP-1-based medicines will be judged on body composition, durability, tolerability, and patient experience.
Research & Knowledge
Drug Hunter